Browse RNF152

Summary
SymbolRNF152
Namering finger protein 152
Aliases FLJ39176; E3 ubiquitin-protein ligase RNF152
Chromosomal Location18q21.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Lysosome membrane Single-pass membrane protein
Domain PF14634 zinc-RING finger domain
Function

E3 ubiquitin-protein ligase mediating 'Lys-63'-linked polyubiquitination of RRAGA in response to amino acid starvation. Thereby, regulates mTORC1 signaling and plays a role in the cellular response to amino acid availability (PubMed:25936802). Also mediates 'Lys-48'-linked polyubiquitination of target proteins and their subsequent targeting to the proteasome for degradation. Induces apoptosis when overexpressed (PubMed:21203937).

> Gene Ontology
 
Biological Process GO:0000209 protein polyubiquitination
GO:0006914 autophagy
GO:0009267 cellular response to starvation
GO:0009991 response to extracellular stimulus
GO:0010506 regulation of autophagy
GO:0010508 positive regulation of autophagy
GO:0031667 response to nutrient levels
GO:0031668 cellular response to extracellular stimulus
GO:0031669 cellular response to nutrient levels
GO:0031929 TOR signaling
GO:0032006 regulation of TOR signaling
GO:0032007 negative regulation of TOR signaling
GO:0034198 cellular response to amino acid starvation
GO:0038202 TORC1 signaling
GO:0042594 response to starvation
GO:0070534 protein K63-linked ubiquitination
GO:0070936 protein K48-linked ubiquitination
GO:0071496 cellular response to external stimulus
GO:1902532 negative regulation of intracellular signal transduction
GO:1903432 regulation of TORC1 signaling
GO:1904262 negative regulation of TORC1 signaling
Molecular Function GO:0004842 ubiquitin-protein transferase activity
GO:0016874 ligase activity
GO:0019787 ubiquitin-like protein transferase activity
GO:0031267 small GTPase binding
GO:0051020 GTPase binding
GO:0061630 ubiquitin protein ligase activity
GO:0061659 ubiquitin-like protein ligase activity
Cellular Component GO:0005765 lysosomal membrane
GO:0031300 intrinsic component of organelle membrane
GO:0031301 integral component of organelle membrane
GO:0098852 lytic vacuole membrane
> KEGG and Reactome Pathway
 
KEGG hsa04150 mTOR signaling pathway
Reactome R-HSA-8866654: E3 ubiquitin ligases ubiquitinate target proteins
R-HSA-392499: Metabolism of proteins
R-HSA-597592: Post-translational protein modification
R-HSA-8852135: Protein ubiquitination
Summary
SymbolRNF152
Namering finger protein 152
Aliases FLJ39176; E3 ubiquitin-protein ligase RNF152
Chromosomal Location18q21.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between RNF152 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolRNF152
Namering finger protein 152
Aliases FLJ39176; E3 ubiquitin-protein ligase RNF152
Chromosomal Location18q21.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of RNF152 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolRNF152
Namering finger protein 152
Aliases FLJ39176; E3 ubiquitin-protein ligase RNF152
Chromosomal Location18q21.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of RNF152 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.6420.0474
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-1.3470.0136
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.1270.795
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.460.205
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.740.645
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.1130.951
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.150.718
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.4650.467
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.2650.695
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.0330.972
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.8910.454
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.5060.000334
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of RNF152 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.72.711
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.73.40.31
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.63.7-1.11
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.57.7-3.21
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolRNF152
Namering finger protein 152
Aliases FLJ39176; E3 ubiquitin-protein ligase RNF152
Chromosomal Location18q21.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of RNF152. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolRNF152
Namering finger protein 152
Aliases FLJ39176; E3 ubiquitin-protein ligase RNF152
Chromosomal Location18q21.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of RNF152. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by RNF152.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolRNF152
Namering finger protein 152
Aliases FLJ39176; E3 ubiquitin-protein ligase RNF152
Chromosomal Location18q21.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of RNF152. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolRNF152
Namering finger protein 152
Aliases FLJ39176; E3 ubiquitin-protein ligase RNF152
Chromosomal Location18q21.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of RNF152 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolRNF152
Namering finger protein 152
Aliases FLJ39176; E3 ubiquitin-protein ligase RNF152
Chromosomal Location18q21.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between RNF152 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolRNF152
Namering finger protein 152
Aliases FLJ39176; E3 ubiquitin-protein ligase RNF152
Chromosomal Location18q21.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting RNF152 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.